Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | PO / MO |
The patient missed the fourth dose of Vivotif.; Case reference number US-BN-2024-000013 is a spontaneous case report initially received from a pharmacist via Med Communications (reference number: USBAV24-0020) on 04-Jan-2024 and concerns a 20-year-old patient of unspecified gender. The patient's relevant medical history and concomitant medications were not provided. On 25-Dec-2023, the patient was vaccinated with the first dose of Vivotif (batch number: unknown), at an unknown dose, orally, for immunization against typhoid fever. On 27-Dec-2023, two days after the first dose of Vivotif, the patient was vaccinated with the second dose of Vivotif (batch number: unknown), at an unknown dose, orally. On 29-Dec-2023, four days after the first dose of Vivotif , the patient was vaccinated with the third dose of Vivotif (batch number: unknown), at an unknown dose, orally. As reported, the patient missed the fourth dose of Vivotif (explicitly coded as 'missed dose'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. No further information was provided.; Reporter's Comments: A 20-year-old patient of unspecified gender missed the fourth dose of Vivotif, after the patient was vaccinated with the first, second and the third dose, which is considered as missed dose. It was unknown if the patient experienced any adverse event due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Product dose omission issue has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 20-year-old patient of unspecified gender missed the fourth dose of Vivotif, after the patient was vaccinated with the first, second and the third dose, which is considered as missed dose. It was unknown if the patient experienced any adverse event due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Product dose omission issue has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.